Back to SearchWritingAvi Bitterman, MD

Writing

Avi Bitterman, MD

@AviMDTracked since May 2026

Observed Aug 13, 2026 · stalePublic earnings

Save Compare Open on Patreon Is this your Patreon? Connect it

creating Research.

How Patreon Signal reads this profile

Identity, tiers, posts, and visible counts come from the latest public Patreon observation. Growth compares available public snapshots. Revenue is labeled observed only when Patreon exposes it; otherwise it is modeled from public membership and tier signals.

Paid members

−11% · 30-day rate from 16 observed days

Total audience

incl. free followers

Observed monthly earnings

$87

Starting price

$5/mo

7 membership tiers

Membership tiers

Where the 82 observed tier members sit

$080.5%$514.6%

Largest observed tier is $0 Free— the bar only uses public tier patron counts.

$0/moFree6680.5% of observed tier members

$5/moKindness Doesn't Need a Reward1214.6% of observed tier members

$10/moYou Are A Saint33.7% of observed tier members

$20/moYou Are Most Gracious11.2% of observed tier members

$50/moYour Gratitude is Legendary00% of observed tier members

$100/moThe Most Appreciated00% of observed tier members

$500/moThe Grand Contributor00% of observed tier members

Growth signals — Avi Bitterman, MD

−11%

16 paid members · 30-day rate from 16 observed days

Membership

181716

May 202616 weeks trackedNow

Avi Bitterman, MD16 members · $87/mo

The chart only uses Avi Bitterman, MD's observed public history. Comparison peers are listed below, but comparable trend series are not available yet.

Creator comparisons

Where Avi Bitterman, MD ranks

5 creators shown

Compare within

Rank by

Paid members Total audience 30-day member gain Estimated gross

#2of 7 measured

Paid members in Recommended cohort

Semantic matches are not ready, so this fixed cohort uses the best available category, audience, pricing, and cadence evidence.

Ranking data · includes stale rows

Avi Bitterman, MD's paid members rank in Recommended cohort
Rank	Creator and why included	Paid members	Gap vs Avi Bitterman, MD	Freshness
#1	PleaseThisWorksWritingCategory, audience, pricing & cadence	17	1 more	Aug 13, 2026
#2	Autumn NicoleWritingCategory, audience, pricing & cadence	16	Same value	Aug 13, 2026
#2	Avi Bitterman, MDProfileWritingPaid members position in Recommended cohort	16	Reference	Aug 13, 2026Stale
#2	AzooDevWritingCategory, audience, pricing & cadence	16	Same value	Aug 13, 2026
#2	BasedVulpineWritingCategory, audience, pricing & cadence	16	Same value	Aug 13, 2026

The rank uses the full fixed cohort. This table shows up to five creators around Avi Bitterman, MD; the coverage summary above still counts everyone.

What they publish

Recent posts

3Profile posts0 postsLast month66.7%Members-only

Previews available for 6 of 3 posts

Image Latest post$5 tier & upNew Publication: Nemolizumab for the Treatment of Refractory Primary Localized Cutaneous Amyloidosis in a Non-Atopic Patient

Link here: https://www.sciencedirect.com/science/article/pii/S2352512625001663?via%3Dihub...

May 21, 2025 0 likes 0 comments

Debunking Sunscreen Myths - Now PublishedImproving patient communication on sunscreen choice:Updating mechanistic misconceptions https://onlinelibrary.wiley.com/doi/10.1002/jvc2.25...ArticleSep 16, 2023$5 tier & up 0 0 The Strongyloidiasis Hypothesis: Now PublishedHappy to announce that I have just published a meta-analysis of randomized clinical trials supporting the hypothesis that Strongyloidiasis prevalence is an effect modifier on mortality in Ivermectin trials for the treatment of COVID-19.ArticleMar 23, 2022Public 0 0 1-s2.0-S2352512625001663-main.pdfNew Publication: Nemolizumab for the Treatment of Refractory Primary Localized Cutaneous Amyloidosis in a Non-Atopic PatientArticleMay 21, 2025$5 tier & up 0 0 JEADV Clinical Practice - 2023 - Zundell (1).pdfImproving patient communication on sunscreen choice:Updating mechanistic misconceptions https://onlinelibrary.wiley.com/doi/10.1002/jvc2.25...ArticleSep 16, 2023$5 tier & up 0 0 The Strongyloidiasis Hypothesis: Now PublishedHappy to announce that I have just published a meta-analysis of randomized clinical trials supporting the hypothesis that Strongyloidiasis prevalence is an effect modifier on mortality in Ivermectin trials for the treatment of COVID-19.ArticleMar 22, 2022Public 0 0

Continue your research

Keep Avi Bitterman, MD in context.

Save the creator, add them to a comparison, or return to the exact Explore view you came from.

Save CompareBack to Search Connect Patreon